Advances in Therapy

, Volume 17, Issue 1, pp 45–55

Early-invasive or early-conservative management of patients with unstable angina or non-Q-wave myocardial infarction

  • Dennis Goodman


The optimal therapy for non-ST-segment-elevation acute coronary syndromes is the subject of considerable debate: is early catheterization and revascularization (early-invasive strategy) or continued medical therapy unless symptoms are refractory (early-conservative strategy) best? Although several clinical trials have sought to answer this question, the methodologies they employed have been widely criticized, and no consensus has been reached. The new antiplatelet therapies have proved beneficial for primary medical management and as adjuncts to percutaneous interventions. It is not yet clear, however, whether use of these therapies will preferentially benefit one of the treatment strategies.


acute coronary syndromes early-invasive strategy earlyconservative strategy glycoprotein IIb/IIIa inhibitors 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb /IIIa integrin in ischemic heart disease.Circulation. 1998; 98: 2829–2835.PubMedGoogle Scholar
  2. 2.
    Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.JAMA. 1999; 281: 1407–1414.PubMedCrossRefGoogle Scholar
  3. 3.
    Topol EJ. What role for catheter laboratories in unstable angina?Lancet. 1998; 352: 500–501.PubMedCrossRefGoogle Scholar
  4. 4.
    Chen L, Chester MR, Redwood S, Huang J, Leatham E, Kaski JC. Angiographic stenosis progression and coronary events in patients with ‘stabilized’ unstable angina.Circulation. 1995; 91: 2319–2324.PubMedGoogle Scholar
  5. 5.
    Adgey AA, Mathew TP, Harbinson MT. Periprocedural creatine kinase-MB elevations: longterm impact and clinical implications.Clin Cardiol. 1999; 22: 257–265.PubMedCrossRefGoogle Scholar
  6. 6.
    Narins CR, Miller DP, Califf RM, Topol EJ. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial.J Am Coll Cardiol. 1999; 33: 647–653.PubMedCrossRefGoogle Scholar
  7. 7.
    Braunwald E, Mark DB, Jones RH, et al.Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10. Rockville, Md: US Dept of Health and Human Services, Agency for Health Care Policy and Research; 1994. AHCPR Publication No. 94-0602.Google Scholar
  8. 8.
    The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial.Circulation. 1994; 89: 1545–1556.Google Scholar
  9. 9.
    Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis In Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.J Am Coll Cardiol. 1995; 26: 1643–1650.PubMedCrossRefGoogle Scholar
  10. 10.
    Boden WE, O’Rourke RA, Crawford MH, the Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy.N Engl J Med. 1998; 338: 1785–1792.PubMedCrossRefGoogle Scholar
  11. 11.
    Tu JV, Sykora K, Naylor CD. Steering Committee of the Cardiac Care Network of Ontario. Assessing the outcomes of coronary artery bypass graft surgery: how many risk factors are enough?J Am Coll Cardiol. 1997; 30: 1317–1323.PubMedCrossRefGoogle Scholar
  12. 12.
    Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI).Circulation. 1997; 96: 748–755.PubMedGoogle Scholar
  13. 13.
    Yusuf S, Flather M, Pogue J, the OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation.Lancet. 1998; 352: 507–514.PubMedCrossRefGoogle Scholar
  14. 14.
    The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.N Engl J Med. 1998; 339: 436–443.CrossRefGoogle Scholar
  15. 15.
    Akkerhuis M, Boersma E, Harrington RA, Deckers JW, Califf RM, Simoons ML. Eptifibatide protects against adverse cardiac complications both before and during percutaneous intervention in patients with acute coronary syndromes without ST-elevation.J Am Coll Cardiol. 1999; 33(suppl A): 40A.Google Scholar
  16. 16.
    Topol EJ, Serruys PW. Frontiers in interventional cardiology.Circulation. 1998; 98: 1802–1820.PubMedGoogle Scholar
  17. 17.
    Topol EJ. Coronary-artery stents—gauging, gorging, and gouging.N Engl J Med. 1998; 339: 1702–1704.PubMedCrossRefGoogle Scholar
  18. 18.
    The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplastycontrolled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/ IIIa blockade.Lancet. 1998; 352: 87–92.CrossRefGoogle Scholar
  19. 19.
    The OASIS Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study.Circulation. 1997; 96: 769–777.Google Scholar
  20. 20.
    The OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial.Lancet. 1999; 353: 429–438.CrossRefGoogle Scholar
  21. 21.
    The FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease.Lancet. 1996; 347: 561–568.Google Scholar
  22. 22.
    Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study.Circulation. 1997; 96: 61–68.PubMedGoogle Scholar
  23. 23.
    Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease.N Engl J Med. 1997; 337: 447–452.PubMedCrossRefGoogle Scholar
  24. 24.
    Cairns JA, Gill J, Morton B, et al. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study.Circulation. 1996; 94: 1553–1560.PubMedGoogle Scholar
  25. 25.
    Karsch KR, Preisack MB, Baildon R, et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE Trial).J Am Coll Cardiol. 1996; 28: 1437–1443.PubMedCrossRefGoogle Scholar
  26. 26.
    The FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronaryartery disease: FRISC II prospective randomised multicentre study.Lancet. 1999; 354: 708–715.CrossRefGoogle Scholar
  27. 27.
    Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial.Am J Cardiol. 1998; 82: 731–736.PubMedCrossRefGoogle Scholar

Copyright information

© Health Communications Inc 2000

Authors and Affiliations

  • Dennis Goodman
    • 1
  1. 1.Division of CardiologyScripps Memorial HospitalLaJolla

Personalised recommendations